This article sheds light on the various scaffolds that can be used in the designing and
development of novel synthetic compounds to create DPP-4 inhibitors for the treatment of …

Diabetes, a metabolic disease caused by abnormally high levels of blood glucose, has a
high prevalence rate worldwide and causes a series of complications, including coronary …

Alzheimer's disease (AD) is a pervasive neurodegenerative disorder, and new approaches
for its prevention and therapy are critically needed. Here, we elucidate a gut-microbiome …

Abstract A series of 1, 2, 4-triazole Schiffs bases 3-9 and their respective acyclo
thioglycosides 10-15 based α-glucosidase and α-amylase inhibitors were synthesized under …

The α‐glucosidase is a validated target to develop drugs for treating type 2 diabetes
mellitus. The existing α‐glucosidase inhibitors have certain shortcomings related to side …

GPR119 agonists are being developed to safeguard the function of pancreatic β‐cells,
especially in the context of non‐alcoholic fatty pancreas disease (NAFPD) that is closely …

Thiazolidinedione (2, 4‐TZD), commonly known as glitazone, is a ubiquitous heterocyclic
pharmacophore possessing a plethora of pharmacological activities and offering a vast …

G protein-coupled receptors (GPCRs) have originally been described as a family of
receptors activated by hormones, neurotransmitters, and other mediators. However, in …

Diabetes Mellitus (DM) is a long-term metabolic condition that is characterized by excessive
blood glucose. DM is the third most death-causing disease, leading to retinopathy …

Dysregulation of glucose metabolism in response to diet-induced obesity contributes toward
numerous complications, such as insulin resistance and hepatic steatosis. Therefore, there …